On this page
Study tools
Write your answer
Saved on this device. No marking — you are the marker.
Stem
A 66-year-old man with type-2 diabetes (HbA1c 9.0%), hypertension, BMI 33 and chronic kidney disease (eGFR 55 mL/min), who has not been vaccinated against SARS-CoV-2, presents to the emergency department with 7 days of fever, dry cough, profound fatigue, and a new loss of smell and taste. Over the last 24 hours he has become progressively breathless. On arrival: he is alert and converses in full sentences but SpO2 is 87% on room air, RR 28, BP 132/82, HR 110, temperature 38.6 degrees C. Chest auscultation is unexpectedly clear with only fine bibasal crackles. ABG on room air: PaO2 7.4 kPa (56 mmHg), PaCO2 4.1 kPa, pH 7.46, lactate 2.4 mmol/L. CXR shows bilateral peripheral mid- and lower-zone opacities; chest CT confirms bilateral, peripheral, posterior-basal ground-glass opacities with areas of crazy-paving and early consolidation. Laboratory investigations: lymphocyte count 0.6 × 10⁹/L, neutrophil/lymphocyte ratio 6, CRP 165 mg/L, ferritin 1300 mcg/L, D-dimer 3.2 mcg/mL, LDH 480 U/L, troponin normal, ALT 65 U/L, creatinine 130 micromol/L. Nasopharyngeal swab SARS-CoV-2 RT-PCR is positive (Ct 22). Respiratory virus panel is otherwise negative; blood cultures sent.
Questions
a) State the diagnosis, the severity stratum, and the four characteristic laboratory abnormalities and their prognostic significance. (2 marks)
The diagnosis is severe COVID-19 pneumonia caused by SARS-CoV-2 (PCR-positive, Ct 22 indicating high viral load) in a high-risk unvaccinated patient (age 66, diabetic, hypertensive, obese, CKD). He meets WHO/NIC severe-disease criteria — SpO2 under 92% on room air (87%), tachypnoea (RR 28), bilateral radiographic infiltrates. The four characteristic laboratory abnormalities and their prognostic significance are: (1) lymphopenia (0.6 × 10⁹/L) — the hallmark of severe COVID-19, reflecting lymphocyte apoptosis in the cytokine storm and a strong adverse prognostic marker; (2) raised CRP (165 mg/L) — a surrogate of the interleukin-6-driven inflammatory response; trajectory (rising) predicts worsening and is the trigger for immunomodulation; (3) raised ferritin (1300 mcg/L) — a marker of macrophage activation and haemophagocytic tendency; very high levels are adverse; (4) raised D-dimer (3.2 mcg/mL) — reflects the COVID-19 hypercoagulable state (endothelialitis, microthrombi, secondary VTE) and is one of the strongest independent predictors of mortality. The raised LDH (480 U/L) is also a tissue-injury/mortality marker. He is at high risk of progression to ARDS, secondary bacterial infection, AKI, VTE/PE and death.
b) Outline the immediate resuscitation and the full first-line inpatient treatment bundle over the next 24 hours, with drug names, doses, routes, monitoring and the evidence/trial rationale for each. (4 marks)
Resuscitation and supportive care: Immediate airborne/droplet isolation; supplemental oxygen to target SpO2 92 to 96% (start on nasal cannula/simple face mask; escalate to high-flow nasal oxygen or CPAP if target not met). Continuous SpO2 and RR monitoring; awake proning in cooperative patients (2-hourly sessions, building to 12 to 16 hours/day) — improves oxygenation by dorsal-lung recruitment and V/Q matching. IV access, bloods, blood cultures, ECG, CXR. Maintain glycaemic control (insulin sliding scale — dexamethasone will worsen hyperglycaemia). Fluid balance — avoid aggressive fluid resuscitation (capillary leak; risk of pulmonary oedema).
First-line drug bundle (NIH/WHO): (1) Dexamethasone 6 mg PO or IV once daily for up to 10 days — RECOVERY trial (NEJM 2021, PMID 32678530): reduced 28-day mortality in patients on oxygen (26% to 21%) and on invasive ventilation (41% to 28%); no benefit and a trend to harm in patients NOT on oxygen. Given ONLY because this patient is hypoxaemic. Monitor: blood glucose, secondary infection, neuromyopathy. (2) Remdesivir 200 mg IV loading dose on day 1, then 100 mg IV OD on days 2 to 5 (total 5 days) — ACTT-1 trial (NEJM 2020, PMID 32445440): shortened median time to recovery from 15 to 10 days in hypoxaemic patients; an RNA-dependent RNA polymerase inhibitor; best benefit in the first 10 days; monitor LFTs (reduce/stop if ALT 5 to 10 times ULN), renal dose adjust. (3) Enoxaparin 40 mg SC OD for VTE prophylaxis (reduce to 20 mg SC OD if eGFR under 30; this patient eGFR 55, full dose) — mandatory in every hospitalised non-bleeding patient because COVID-19 produces a striking hypercoagulable state (D-dimer 3.2 here). (4) Tocilizumab 8 mg/kg IV single infusion (max 800 mg; repeat once after 8 to 12 h if no response) OR baricitinib 4 mg PO OD for up to 14 days — indicated for rapidly progressing severe/critical disease with rising CRP/ferritin within 24 hours of new high-flow oxygen/ventilation (REMAP-CAP tocilizumab; baricitinib COV-BARRIER); he is a candidate given the high inflammatory profile — consider if markers continue to rise or oxygen requirement escalates. (5) Prophylactic proton-pump inhibitor (dexamethasone-related GI bleeding risk). (6) Empiric antibiotics ONLY if documented/suspected secondary bacterial infection — not routinely; check procalcitonin and cultures.
Escalation triggers for ICU — worsening hypoxaemia (SpO2 under 92% despite HFNO/NIV), rising RR over 30, rising work of breathing, fatigue, haemodynamic instability, multi-organ failure, altered consciousness — intubate EARLY (do not wait for crash).
c) The patient deteriorates on day 3 of admission: SpO2 84% on 15 L/min via non-rebreather, RR 35, with increasing work of breathing and ABG PaO2/FiO2 ratio of 95 (PEEP via CPAP 5 cmH2O). State the diagnosis using the Berlin definition, and outline the ICU management including the ventilator strategy and adjuncts. (2 marks)
The PaO2/FiO2 ratio of 95 with bilateral opacities, within 1 week of symptom onset, in the absence of primary cardiac failure, with PEEP at least 5 cmH2O, meets severe ARDS by the Berlin definition (P/F under 100 = severe). He requires invasive mechanical ventilation. Management bundle: (1) Lung-protective ventilation — tidal volume 6 mL/kg predicted body weight, plateau pressure under 30 cmH2O, driving pressure under 15 cmH2O, individualised PEEP titration (high PEEP may worsen the COVID 'Type-L' low-elastance phenotype); (2) Prone positioning for 16 hours per day — improves oxygenation and reduces ARDS mortality; (3) Deep sedation and short-course neuromuscular blockade (cisatracurium) if patient-ventilator asynchrony or P/F under 150; (4) Continue dexamethasone, remdesivir (until 5-day course complete), LMWH (prophylactic in ICU; therapeutic only if confirmed VTE — REMAP-CAP/ATTACC/ACTIV-4a: therapeutic-dose anticoagulation is HARMFUL in critically-ill ICU patients); (5) Renal replacement therapy if AKI with refractory hyperkalaemia, acidosis, fluid overload; (6) Inhaled pulmonary vasodilators (nitric oxide, epoprostenol) as rescue for refractory hypoxaemia; (7) Venovenous ECMO in expert centre for refractory severe ARDS. Stress-ulcer prophylaxis, DVT prophylaxis, glycaemic control, nutrition, delirium prevention as standard ICU bundle.
d) The patient survives but is readmitted 8 weeks later with persistent disabling fatigue, breathlessness on minimal exertion, and difficulty concentrating at work, with no alternative diagnosis identified. State the syndrome, the WHO diagnostic criteria, and the principles of management. (2 marks)
This is the post-COVID condition ('long COVID'). WHO diagnostic criteria (2021): symptoms that develop within 3 months of the onset of COVID-19, last for at least 2 months, and cannot be explained by an alternative diagnosis. Common manifestations include fatigue (most common, often with post-exertional malaise), breathlessness, cognitive dysfunction ('brain fog'), persistent anosmia/ageusia, autonomic dysfunction (POTS-like postural tachycardia), cough, sleep disturbance, and mental-health sequelae (depression, anxiety, PTSD). Management is symptom-focused and rehabilitative, multidisciplinary: (1) pacing for fatigue and post-exertional malaise — avoid aggressive graded-exercise reconditioning which can worsen symptoms; (2) pulmonary rehabilitation for breathlessness; (3) cognitive rehabilitation for brain fog; (4) investigate and treat organ-specific disease — cardiac (myocarditis), respiratory (organising pneumonia/post-ARDS fibrosis — may respond to a trial of corticosteroid), thrombotic (anticoagulation), endocrine (new-onset diabetes); (5) mental-health support; (6) multidisciplinary post-COVID clinic. There is no single biomarker or specific antiviral; management is individualised. Prognosis is generally favourable over months, but a subset of patients have persistent symptoms beyond 12 months.